How COVID-19 Is Driving RWE Uptake In Clinical Trials
With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.
You may also be interested in...
Real-World Data: ‘Don’t Take Your Foot Off The Gas’
It is possible to maintain the current focus on the use of real-world data in drug development by finding simple solutions to existing challenges, argues an expert at a US-based RWD platform.
EMA To Explain How Trial Transparency & Data Redaction Can Live Together
The European Medicines Agency is working to align the redaction and data anonymization principles underpinning two EU clinical trial transparency initiatives to ensure consistency in disclosure requirements.
ICH Consults On Modernized GCP Principles To Make Clinical Trials More Efficient
The International Council for Harmonisation has issued updated Good Clinical Practice principles to accommodate new clinical trial and data types.